SCHEMBL2273169

SCHEMBL2273169

O=C(C=Cc1cccs1)Nc1cc(Oc2ccccc2)ccc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.54
NPC1 O15118 10/20 0.54
SMN1; SMN2 Q16637 9/20 0.54
KMT2A Q03164 7/20 0.47
MAPT P10636 7/20 0.47
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 5/20 0.47
TDP1 Q9NUW8 2/20 0.47
UBE2I P63279 2/20 0.47
SAE1 Q9UBE0 2/20 0.47
UBA2 Q9UBT2 2/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.47
BLM P54132 1/20 0.47
HKDC1 Q2TB90 1/20 0.47
MEN1 O00255 6/20 0.47
HTT P42858 4/20 0.47
LMNA P02545 3/20 0.47
TP53 P04637 2/20 0.47
PSMD14 O00487 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273164 1.00 RAB9A (0.54) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL2270176 0.83 TRPA1 (0.60) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL2270181 0.83 TRPA1 (0.60) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL5147438 0.83 RAB9A (0.57) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL5147433 0.83 RAB9A (0.57) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL27731432 0.82 ALDH1A1 (0.62) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL13854028 0.82 RAB9A (0.69) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL9767854 0.82 RAB9A (0.69) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL9768217 0.81 RAB9A (0.67) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL2278127 0.80 TRPA1 (0.62) RAB9ANPC1SMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 RAB9A 2238/4885NPC1 4836/4885SMN1; SMN2 3544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.